Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities.
STAMFORD, Conn., Sept. 26, 2019 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a Company presentation at the 2019 Cantor Fitzgerald Global Healthcare Conference on Thursday, October 3, 2019 at 4:10 p.m. ET in New York, NY.
